Adoptive immunotherapy with purified NK or T cells (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Adoptive immunotherapy with purified NK or T cells (Meeting abstract).

Biological Response Modifiers, 2nd International Congress. January 29-31. 1993, San Diego, CA, p. 79, 1993.. Unique Identifier : AIDSLINE ICDB/94698353
Herberman RB; Pittsburgh Cancer Inst., Pittsburgh, PA

Abstract: Adoptive transfer of peripheral blood lymphocytes with lymphokine-activated killer (LAK) activity or of tumor infiltrating lymphocytes, together with high doses of interleukin 2 (IL2), has been shown to have therapeutic efficacy against metastatic tumors in some experimental animal models and in some cancer patients, particularly those with renal cell carcinoma or melanoma. However, the frequency of objective responses has been low and the high doses of IL2 utilized have contributed to substantial toxicity. The challenge is to develop second generation therapeutic protocols, to optimize therapeutic efficacy and to reduce toxicity. We have focused on the use of defined, highly purified lymphocyte populations which have been shown to contain cytolytic effector cells. Since LAK activity in peripheral blood is generated predominantly from natural killer (NK) cells, we have developed a procedure to consistently isolate highly enriched populations of IL2 activated NK cells, based on the ability of a subset of such cells to adhere to plastic. These A-NK cells, when administered together with moderate doses of IL2, have been shown to have potent antimetastatic effects against several experimental tumors in mice or rats. Transfer of fluorescently labeled A-NK cells has shown selective accumulation of a small proportion of the effector cells in sites of metastasis. A preliminary clinical trial with autologous A-NK cells has demonstrated the feasibility of this approach in advanced cancer patients. An analogous approach has recently been utilized for the treatment of HIV-infected individuals, in which autologous CD8+ T cells have been isolated by a solid phase capture device (Applied Immune Sciences), expanded in culture with IL2, and infused iv. These purified T cells have been shown to have significant and specific cytotoxic activity against HIV-infected target cells and a separate clinical trial at the University of Miami (N Klimas, PI) has shown objective responses in some patients with Kaposi's sarcoma.

Keywords: Animal HIV Infections/IMMUNOLOGY *Immunotherapy Kidney Neoplasms/IMMUNOLOGY/*THERAPY *Killer Cells, Lymphokine-Activated *Killer Cells, Natural Melanoma/IMMUNOLOGY/*THERAPY ABSTRACT
940530
M9450895

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .